Charles River Laboratories International, Inc. vs Abbvie Inc.
CRL vs ABBV — side-by-side comparison from reported financials. CRL leads 4, ABBV leads 6 of 10 comparable metrics.
Charles River Laboratories International, Inc.
CRL · Healthcare
$301.79+1.27%Strained
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | CRL | ABBV |
|---|---|---|
| Price | $301.79 | $276.43 |
| Market cap | $14.4B | $488B |
| Revenue (TTM) | $4.00B | $64.4B |
| Revenue growth | +0.3% | +1.8% |
| Net margin | -6.0% | 9.8% |
| Free cash flow | $371M | $18.2B |
| Net cash (debt) | ($1.92B) | ($56.2B) |
| 1-year price return | +75.3% | +19.8% |
| P/E | 20.8 | 77.4 |
| P/E vs own history (cheap-side %) | 98% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | -8% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 5 of 10 | 9 of 10 |
| Employees | 19,700 | 57,000 |
Full résumé-style profiles: CRL CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.